pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

2,039 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1554Endpoints1218BioSpace559Fierce Biotech554BioPharma Dive464raps192onclive165fda recalls102
therapy area
allOncology10363Rare Disease2700Immunology2440Cardiology2281Hematology1880Pulmonology1872Vaccines
  • Key criteria for selecting a biologics CDMO: reliability, cost, technology and partnership fit
    Choosing the right contract development and manufacturing organization is a strategic move for biotech and biopharma firms, as it can speed development and lower regulatory risk. The top priority…
    Fierce Biotech · 18d agoNeutral↗ source
  • Immunotherapy startup Adecto shuts down, citing risk-averse funding climate
    Adecto Pharmaceuticals, a Boston-based immunotherapy biotech founded in 2014 by Tufts researchers, announced it is closing after 12 years. The company had been developing AD100, a monoclonal antib…
    Fierce Biotech · 19d agoNegative↗ source
← prev
page 11 of 82
next →
fda medwatch93
globenewswire health73
fda press54
1617
Psychiatry & CNS1106
Ophthalmology844
Endocrinology & Metabolism687
Pain654
Nephrology634
Flowers Foods recalls Nature’s Own Hawaiian Bread after discovering undeclared milk allergen
Flowers Foods announced on October 2, 2026 that it is pulling its Nature’s Own Hawaiian Bread from the market. The recall covers both the 20‑ounce loaves and the 40‑ounce two‑pack versions sold und…
fda recalls · 18d agoCRLNegative↗ source
  • EAK Distribution recalls Home Grown broccoli seed packets over possible Salmonella contamination
    EAK Distribution LLC announced on October 2, 2026 that it is recalling its 8‑oz Home Grown Green Sprouting Calabrese Broccoli Seeds due to a potential Salmonella contamination. The company warned…
    fda recalls · 18d agoRegulatoryNegative↗ source
  • Frutas y Hortalizas del Sur expands recall to more Great Value and Trader Joe's frozen berry products over E. coli risk
    Frutas y Hortalizas del Sur S.A., a Chilean producer, announced on Oct 2, 2026 that it is expanding its earlier recalls of frozen organic berries. The expansion adds additional lots of Great Value…
    fda recalls · 18d agoCRLNeutral↗ source
  • Sanofi to pay $1 billion upfront to expand antibody partnership with Regeneron
    Sanofi announced it will provide Regeneron with a $1 billion upfront payment to broaden their existing antibody collaboration. The agreement is timed as the patent protection for Dupixent, the joi…
    Endpoints · 19d agoDealNeutral↗ source
  • Sanofi pays Regeneron $1 billion upfront to co-develop four early-stage immunology assets
    Sanofi has agreed to pay Regeneron an upfront fee of $1 billion to partner on four early‑stage immunology programs, a move intended to capture the success of their joint Dupixent antibody. Dupixen…
    Fierce Biotech · 20d agoDealPositive↗ source
  • Devoted Health secures $1.2 billion in new funding to fuel senior member growth
    Devoted Health, a Medicare Advantage insurer and medical group, announced a fresh capital injection of nearly $1.2 billion. The financing round includes a $555 million Series G investment along wi…
    Endpoints · 19d agoDealPositive↗ source
  • Roche Diagnostics unveils single-assay newborn test for SMA, SCID and Sickle Cell Disease
    Roche Diagnostics introduced a new in‑vitro diagnostic kit called LightMix Newborn TREC/SMN1/HBB that can screen newborns for three rare genetic disorders in a single test. The assay simultaneousl…
    Fierce Biotech · 19d agoPositive↗ source
  • Foghorn Therapeutics cuts 40% of staff after Lilly partnership ends over weak phase-1 data
    Foghorn Therapeutics announced it will lay off 40% of its workforce after its long‑standing collaboration with Eli Lilly fell apart due to disappointing phase‑1 trial results. The partnership, lau…
    Fierce Biotech · 19d agoLayoffsNegative↗ source
  • Zealand Pharma shares tumble 12% after Boehringer obesity drug trial meets endpoints but disappoints analysts
    A phase 3 trial of Boehringer Ingelheim's dual‑agonist drug survodutide in people with obesity and type 2 diabetes was presented at the European Association for the Study of Diabetes meeting in Mil…
    Fierce Biotech · 20d agoNegative readoutNegative↗ source
  • United Therapeutics wins Delaware court case; BMS secures pediatric approval for Camzyos
    United Therapeutics secured a legal victory in a federal court in Delaware, with the judge ruling in the company's favor. The decision marks a notable win for the biotech firm, though the specific…
    Endpoints · 19d agoApprovalNeutral↗ source
  • Eli Lilly ends partnership with Foghorn Therapeutics, prompting 40% staff cut at biotech
    Eli Lilly announced it is withdrawing from its collaboration with Foghorn Therapeutics on a synthetic lethality drug program. Following the pullback, Foghorn said it will cut roughly 40% of its wo…
    Endpoints · 19d agoDealNegative↗ source
  • Regeneron antibody restores muscle loss in patients after stopping Wegovy, mid-stage data show
    Regeneron presented new mid-stage data at the European Association for the Study of Diabetes (EASD) meeting in Milan showing its investigational antibody can help patients with obesity recover musc…
    Endpoints · 19d agoPositive readoutPositive↗ source
  • Kallyope rebrands as TriGemX Bio, secures $94M to fund Phase 3 migraine trial
    Kallyope, a New York City drug developer, announced it is changing its name to TriGemX Bio as it narrows its pipeline to migraine. The rebrand follows a recent partnership with Novo on an obesity…
    Endpoints · 19d agoDealPositive↗ source
  • BMS trial sees patient death, analysts say drug mechanism still viable
    Bristol Myers Squibb is running a phase 3 study of an LPA1 inhibitor, admilparant, for idiopathic and progressive pulmonary fibrosis. A patient death was reported after the trial was amended to inc…
    Fierce Biotech · 19d agoNeutral↗ source
  • Boehringer's obesity drug shows up to 9.8% weight loss in diabetes patients but lags behind competitors
    Boehringer Ingelheim presented data at the European Association for the Study of Diabetes (EASD) meeting in Milan, showing its lead obesity candidate achieved up to 9.8% weight reduction in a late-…
    Endpoints · 20d agoNegative readoutNeutral↗ source
  • Study finds AI may be driving up healthcare costs
    A recent analysis by the Blue Cross Blue Shield Association challenges the common belief that artificial intelligence will lower healthcare spending. The report argues that, instead of delivering…
    Endpoints · 19d agoNegative↗ source
  • Anthropic AI reports first scientific discovery: new enzyme system
    Anthropic announced that its Claude AI system has identified a previously unknown enzyme system, marking the company's first reported scientific discovery. The life sciences team, led by Eric Kaud…
    Endpoints · 19d agoPositive↗ source
  • Parakeet Health secures $10 million to expand AI-driven patient outreach platform
    Parakeet Health, a health-tech startup, announced it has raised $10 million in funding, according to Endpoints News. The capital will be used to scale its AI-powered platform that contacts patient…
    Endpoints · 19d agoDealPositive↗ source
  • Bayer names Christoph Koenen as new chief medical officer as Eric Cantor becomes PhRMA CEO
    Bayer announced that Christoph Koenen, M.D., has been appointed as its new chief medical officer. Koenen, who joined Bayer in 2022 after roles at Bristol Myers Squibb, Novo, Boehringer and GSK, wil…
    Fierce Biotech · 19d agoNeutral↗ source
  • House lawmakers hear mixed views on credentialing for psychedelic providers
    As psychedelic medicines move closer to market, two members of the U.S. House are outlining how the drugs might be rolled out and what accompanying legislation could look like. The focus of their…
    Endpoints · 19d agoRegulatoryNeutral↗ source
  • Greenwich Rx voluntarily recalls compounded glutathione injections over possible elevated endotoxin levels
    Greenwich Rx, a 503A compounding pharmacy based in Tomball, Texas, announced a voluntary nationwide recall of specific lots of its compounded glutathione injection product. The recall is being issu…
    fda recalls · 19d agoCRLNegative↗ source
  • Saint Francis Apizza recalls frozen pizzas over undeclared soy allergen
    Saint Francis Apizza LLC announced a voluntary recall of several frozen pizza varieties because soy allergen was not listed on the label. The affected products include Pepperoni, Plain Cheese, Sup…
    fda recalls · 20d agoCRLNegative↗ source
  • Gias Foods recalls Bettergoods Lemon Alfredo Fettuccine over possible Listeria contamination
    Gias Foods of New York announced a recall of all lot codes of its Bettergoods Authentic Italian Lemon Alfredo Fettuccine after routine testing indicated possible contamination with Listeria monocyt…
    fda recalls · 20d agoRegulatoryNegative↗ source